2-Methyl-3-(2-methylphenyl)prop-2-enoic acid | 103987-51-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 2-Methyl-3-(2-methylphenyl)prop-2-enoic acid
• CAS: 103987-51-5
• 化学式: C₁₁H₁₂O₂
• 分子量: 176.215
• InChiKey: LUPFTDWCMOPSIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Methyl-3-(2-methylphenyl)prop-2-enoic acid 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  α-烷基 α,β-不饱和酯中的对映和非对映选择性硼共轭加成

  摘要：

  我们在无碱条件下开发了一种铜催化的对映选择性和非对映选择性硼共轭加成到 α-烷基 α,β-不饱和酯中。该方法显示出出色的对映选择性 (87–99% ee) 和中等至良好的转化率 (51–99%)，尽管具有中等的非对映选择性 (1 : 1–17 : 1 dr)。证明了该协议的综合效用。

  DOI：

  10.1039/d2ob01928k
• 作为产物：
  描述：

  2-甲基苯甲醛 在 三乙烯二胺 、 甲醇 、 copper(II) choride dihydrate 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.25h， 生成 2-Methyl-3-(2-methylphenyl)prop-2-enoic acid
  参考文献：
  名称：

  α-烷基 α,β-不饱和酯中的对映和非对映选择性硼共轭加成

  摘要：

  我们在无碱条件下开发了一种铜催化的对映选择性和非对映选择性硼共轭加成到 α-烷基 α,β-不饱和酯中。该方法显示出出色的对映选择性 (87–99% ee) 和中等至良好的转化率 (51–99%)，尽管具有中等的非对映选择性 (1 : 1–17 : 1 dr)。证明了该协议的综合效用。

  DOI：

  10.1039/d2ob01928k

文献信息

• Iridium-Catalyzed Enantioselective Hydrogenation of α,β-Unsaturated Carboxylic Acids
  作者：Shen Li、Shou-Fei Zhu、Can-Ming Zhang、Song Song、Qi-Lin Zhou

  DOI：10.1021/ja802399v

  日期：2008.7.1

  A highly efficient iridium-catalyzed hydrogenation of alpha,beta-unsaturated carboxylic acids has been developed by using chiral spiro-phosphino-oxazoline ligands, affording alpha-substituted chiral carboxylic acids in exceptionally high enantioselectivities and reactivities.

  已经通过使用手性螺-膦基-恶唑啉配体开发了一种高效的铱催化氢化 α,β-不饱和羧酸，从而以极高的对映选择性和反应性提供 α-取代的手性羧酸。
• BENZOTRIAZOLE COMPOUND
  申请人：MIYOSHI OIL & FAT CO.,LTD.

  公开号：US20200325107A1

  公开（公告）日：2020-10-15

  Provided is a benzotriazole compound that efficiently absorbs ray having a long wavelength of 360-400 nm, i) having excellent solubility in a monomer of a resin raw material, being dissolvable at a high concentration, polymerizing at excellent reactivity, and yielding a high-molecular-weight resin member and a transparent resin member, or ii) having exceptional heat resistance. This benzotriazole compound is represented by formula (I), where at least one of R 1 -R 9 is represented by formula (i-1), (where R 10 and R11 are hydrocarbon groups, etc., and R 12 is represented by formula (i-2) or formula (i-3) (in formula (i-2), A 1 represents a divalent group selected from nitrogen-Containing groups, oxygen-containing groups, sulfur-containing groups, phosphorus-containing groups, and phenylene groups, and R 12a -R 12c and X represent hydrocarbon groups, etc.; and in formula (i-3), A 2 represents a divalent group selected from nitrogen-containing groups, oxygen-containing groups, sulfur-containing groups, and phosphorus-containing groups, and X a and X b represent hydrocarbon groups, etc.)).

  提供了一种苯并三唑化合物，能够高效吸收波长在360-400纳米之间的射线，i）在树脂原料的单体中具有优良的溶解性，能够以高浓度溶解，具有优异的反应性进行聚合，形成高分子量树脂成员和透明树脂成员，或者ii）具有异常的耐热性。该苯并三唑化合物由式（I）表示，其中R1-R9中至少一个由式（i-1）表示，（其中R10和R11为碳氢基团等，R12由式（i-2）或式（i-3）表示（在式（i-2）中，A1表示从氮含基团、氧含基团、硫含基团、磷含基团和苯基团中选择的二价基团，R12a-R12c和X表示碳氢基团等；在式（i-3）中，A2表示从氮含基团、氧含基团、硫含基团和磷含基团中选择的二价基团，Xa和Xb表示碳氢基团等）。
• [EN] 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] INHIBITEURS DE BÊTA-SÉCRÉTASE DE TYPE PYRROLIDINES 3,4-SUBSTITUÉES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2009078932A1

  公开（公告）日：2009-06-25

  The present invention is directed to 3,4-substituted pyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式(I)的3,4-取代吡咯烷化合物，其为β-分泌酶酶抑制剂，可用于治疗涉及β-分泌酶酶的疾病，如阿尔茨海默病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗涉及β-分泌酶酶的疾病中的用途。
• 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Stachel Shawn J.

  公开号：US20100280009A1

  公开（公告）日：2010-11-04

  The present invention is directed to 3,4-substituted pyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及公式（I）的3,4-取代吡咯烷化合物，其为β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，例如阿尔茨海默病中有用。本发明还涉及包含这些化合物的药物组合物以及在治疗β-分泌酶酶参与的这些疾病中使用这些化合物和组合物的用途。
• PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME
  申请人：BIO-PHARM SOLUTIONS CO., LTD.

  公开号：US20150266848A1

  公开（公告）日：2015-09-24

  The present invention relates to novel phenylalkyl sulfamate compounds, a method for preventing or treating a disease associated with muscle spasm. The present invention ensures the enhancement of muscle relaxation activity essential for alleviation of muscle spasm, such that it is promising for preventing or treating various diseases associated with muscle spasm.

  本发明涉及一种新型的苯基烷基磺酰胺化合物，以及一种预防或治疗与肌肉痉挛有关的疾病的方法。本发明确保增强肌肉松弛活性，这对于缓解肌肉痉挛至关重要，因此本发明有望预防或治疗与肌肉痉挛有关的各种疾病。